Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067478 · ClinicalTrials.gov registry record
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
A clinical trial, sponsored by Urovant Sciences.
- Completed
- Registry status
- 403
- Enrollment target
NCT05067478 is a clinical trial that has completed, run by Urovant Sciences. The registered enrollment target is 403 participants.
The verdict
NCT05067478 has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- 403 participants
- Enrollment target
Study Summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
Interventions
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-07-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067478
The ClinicalTrials.gov registry entry for NCT05067478 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vibegron is the first listed.
NCT05067478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05067478 about?
NCT05067478 is a clinical study titled "Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)". This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
What is the current status of trial NCT05067478?
This trial is currently completed. The enrollment target is 403 participants. The study started on 2021-10-28. Estimated completion is 2024-07-26.
What interventions are being tested in trial NCT05067478?
The interventions under investigation include: Vibegron (DRUG).
Who is sponsoring clinical trial NCT05067478?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.